Literature DB >> 19280186

Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics.

Ludwig G Strauss1, Johannes Hoffend, Dirk Koczan, Leyun Pan, Uwe Haberkorn, Antonia Dimitrakopoulou-Strauss.   

Abstract

PURPOSE: The very early chemotherapeutic effects of the FOLFOX (fluorouracil, folinic acid, oxaliplatin) protocol were assessed in mice implanted with a human colorectal cell line. The aim of this study was to identify changes in gene expression patterns and to detect combinations of PET parameters that may be helpful in identifying treated tumours early after chemotherapy using dynamic PET studies.
METHODS: A human colorectal cell line (HCT 116) was used in nude mice. Dynamic PET studies were performed in untreated (n = 13) and treated (n = 12) animals. The data were assessed using compartmental and noncompartmental analysis. The removed tumour specimens were assessed by gene array analysis to obtain quantitative information on gene expression.
RESULTS: One chemotherapeutic treatment using the FOLFOX protocol resulted in an upregulation of 2,078 gene probes by more than 25%, while 2,254 probes were downregulated following treatment. The gene array data demonstrated primarily an enhancement of genes related to apoptosis. In particular, the apoptosis antigen 1 (APO-1), p21 and the G protein-coupled receptor 87 (G-87) were 2.6- to 3.3-fold upregulated as compared to the expression in untreated animals. There was a 100% separation of untreated and treated animals on the basis of these three genes. The SUV and the FDG kinetic parameters obtained by compartmental and noncompartmental fitting were not significantly different when individual parameters were compared between groups. However, classification analysis of the combination of the PET parameters VB, K1, k3, and influx revealed an overall accuracy of 84%. We were able to identify 91.7% (11/12) of the treated animals and 76.9% (10/13) of the untreated animals correctly using the classification analysis of PET data.
CONCLUSION: Even one chemotherapeutic treatment using FOLFOX has an impact on gene expression and significantly modulates FDG kinetics. Quantitative assessment of the tracer kinetics and the application of classification analysis to the data are promising tools to identify those tumours that demonstrate a chemotherapeutic effect very early following treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19280186     DOI: 10.1007/s00259-009-1102-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  23 in total

1.  Activation changes the spectrum but not the diversity of genes expressed by T cells.

Authors:  T K Teague; D Hildeman; R M Kedl; T Mitchell; W Rees; B C Schaefer; J Bender; J Kappler; P Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  Applications of support vector machines to cancer classification with microarray data.

Authors:  Feng Chu; Lipo Wang
Journal:  Int J Neural Syst       Date:  2005-12       Impact factor: 5.866

3.  Fusion of positron emission tomography (PET) and gene array data: a new approach for the correlative analysis of molecular biological and clinical data.

Authors:  Ludwig G Strauss; Leyun Pan; Dirk Koczan; Sven Klippel; Krzysztof Mikolajczyk; Cyrill Burger; Uwe Haberkorn; Klaus Schönleben; Hans-Jürgen Thiesen; Antonia Dimitrakopoulou-Strauss
Journal:  IEEE Trans Med Imaging       Date:  2007-06       Impact factor: 10.048

4.  FLASH links the CD95 signaling pathway to the cell nucleus and nuclear bodies.

Authors:  Kristijana Milovic-Holm; Eva Krieghoff; Kirsten Jensen; Hans Will; Thomas G Hofmann
Journal:  EMBO J       Date:  2007-01-24       Impact factor: 11.598

Review 5.  The applications of PET in clinical oncology.

Authors:  L G Strauss; P S Conti
Journal:  J Nucl Med       Date:  1991-04       Impact factor: 10.057

6.  Enhanced susceptibility of oral squamous cell carcinoma cell lines to FAS-mediated apoptosis by cisplatin and 5-fluorouracil.

Authors:  Masayasu Iwase; Hitoshi Watanabe; Gen Kondo; Masaru Ohashi; Masao Nagumo
Journal:  Int J Cancer       Date:  2003-09-10       Impact factor: 7.396

7.  Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.

Authors:  Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Cyrill Burger; Anne Rühl; Gisela Irngartinger; Wolfgang Stremmel; Jochen Rudi
Journal:  J Nucl Med       Date:  2004-09       Impact factor: 10.057

Review 8.  Colorectal cancer: integrating oxaliplatin.

Authors:  Christophe Louvet; Aimery de Gramont
Journal:  Curr Treat Options Oncol       Date:  2003-10

9.  hGPR87 contributes to viability of human tumor cells.

Authors:  Sebastian Glatt; Daniel Halbauer; Stefan Heindl; Andreas Wernitznig; Daniela Kozina; Kuan-Chung Su; Christina Puri; Pilar Garin-Chesa; Wolfgang Sommergruber
Journal:  Int J Cancer       Date:  2008-05-01       Impact factor: 7.396

10.  Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines.

Authors:  Tatiana V Rakitina; Irina A Vasilevskaya; Peter J O'Dwyer
Journal:  Biochem Pharmacol       Date:  2007-02-04       Impact factor: 5.858

View more
  2 in total

1.  Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal ¹⁸F-FDG PET and gene expression analysis.

Authors:  Maren Bretschi; Caixia Cheng; Hendrik Witt; Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Wolfhard Semmler; Tobias Bäuerle
Journal:  J Cancer Res Clin Oncol       Date:  2012-12-11       Impact factor: 4.553

2.  The Potential Benefit by Application of Kinetic Analysis of PET in the Clinical Oncology.

Authors:  Mustafa Takesh
Journal:  ISRN Oncol       Date:  2012-12-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.